Low penetrance, broad resistance and favorable outcome of interlenkin 12 receptor betal deficiency: medical and immunological implications

Research output: Contribution to journalArticle


  • C Fiesci
  • S Dupuis
  • E Catherinot
  • J Feinberg
  • J Bustamante
  • A Breiman
  • F Altare
  • F Le Deist
  • H Koch
  • D Richter
  • M Brezina
  • G Aksu
  • S Al-Jumaah
  • M Raspall
  • AJ Da Silva Duarte
  • D Tuerlinckx
  • JL Virelizier
  • A Fischer
  • A Enright
  • J Bernhoft
  • AM Cleary
  • C Vermylen
  • C Rodriguez-Gallego
  • G Davies


The clinical phenotype of interleukin 12 receptor beta1 chain (IL-12Rbeta1) deficiency and the function of human IL-12 in host defense remain largely unknown, due to the small number of patients reported. We now report 41 patients with complete IL-12Rbeta1 deficiency from 17 countries. The only opportunistic infections observed, in 34 patients, were of childhood onset and caused by weakly virulent Salmonella or Mycobacteria (Bacille Calmette-Guerin -BCG- and environmental Mycobacteria). Three patients had clinical tuberculosis, one of whom also had salmonellosis. Unlike salmonellosis, mycobacterial infections did not recur. BCG inoculation and BCG disease were both effective against subsequent environmental mycobacteriosis, but not against salmonellosis. Excluding the probands, seven of the 12 affected siblings have remained free of case-definition opportunistic infection. Finally, only five deaths occurred in childhood, and the remaining 36 patients are alive and well. Thus, a diagnosis of IL-12Rbeta1 deficiency should be considered in children with opportunistic mycobacteriosis or salmonellosis; healthy siblings of probands and selected cases of tuberculosis should also be investigated. The overall prognosis is good due to broad resistance to infection and the low penetrance and favorable outcome of infections. Unexpectedly, human IL-12 is redundant in protective immunity against most microorganisms other than Mycobacteria and Salmonella. Moreover, IL-12 is redundant for primary immunity to Mycobacteria and Salmonella in many individuals and for secondary immunity to Mycobacteria but not to Salmonella in most.


Original languageEnglish
Pages (from-to)527-35
Number of pages9
JournalThe Journal of Experimental Medicine
Publication statusPublished - 17 Feb 2003


  • interleukin 12 receptor, Mycobacteria, immunodeficiency, Salmonella, interferon gamma

Sustainable Development Goals